Custom C-to-G Base Editor (AAV)
Custom C-to-G Base Editor (AAV)
SKU:
Couldn't load pickup availability
Direct C-to-G transversion editing in single-AAV format for in vivo gene therapy. Enables unique base conversions inaccessible to adenine or cytosine base editors for correcting transversion mutations in liver, muscle, CNS, and other AAV-accessible tissues. Compact architecture eliminates dual-vector requirements while delivering novel editing capability for therapeutic applications requiring guanine installation at cytosine positions.
- CGBE Base Editor: C-to-G transversion base editor expanding beyond transition mutations. Enables targeted C-to-G conversion addressing 11-40% of disease SNPs.
- bGH PolyA Signal: Compact (225 bp) polyadenylation signal from bovine growth hormone with 3-fold higher expression than SV40 early polyA in key mammalian cell types. Size advantage over SV40 polyA makes it the preferred terminator for AAV vectors with limited cargo space. Standard terminator in commercial gene therapy and lentiviral vector platforms with decades of in vivo validation.
- U6 Promoter: RNA polymerase III promoter that drives constitutive expression of small RNAs. Provides strong, stable transcription with precise transcriptional start and termination sites.
Deliverables
- Titer: 1e13 VG/mL or higher
- Full Capsid Ratio: 0.85 or higher
- Delivery Timeline: 18–21 days
Specifications
Single stranded AAV produced in 293T cells and purified through two (2) rounds of CsCl ultracentrifugation and stored in 0.001% F-68 in DPBS with additional 150 mM NaCl. Ships on dry ice overnight.
This construct can be packaged in hundreds of AAV serotypes to target your specific tissue. We offer all standard serotypes (AAV1-9) plus specialized variants for muscle (MyoAAV-2A, MyoAAV-1A, AAVMyo), brain (PHP.eB, AAV9P31, AAV2-retro), and clinical applications (AAV2, Spark100). Other popular options include AAV-rh.74, AAV6, AAV6.2FF, and AAV3. Browse our complete serotype library or contact us for recommendations.
References
Share
